Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children. Pichichero, M., Casey, J., Blatter, M., Rothstein, E., Ryall, R., Bybel, M., Gilmet, G., & Papa, T. Journal January 2005, 24(1):57–62, 2005.
Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children [link]Paper  abstract   bibtex   
Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135)., Methods: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples., Results: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P \textless 0.001 for all comparisons). This significant difference persisted through 6 months., Conclusions: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine., (C) 2005 Lippincott Williams & Wilkins, Inc.
@article{pichichero_comparative_2005,
	title = {Comparative {Trial} of the {Safety} and {Immunogenicity} of {Quadrivalent} ({A}, {C}, {Y}, {W}-135) {Meningococcal} {Polysaccharide}-{Diphtheria} {Conjugate} {Vaccine} {Versus} {Quadrivalent} {Polysaccharide} {Vaccine} in {Two}- to {Ten}-{Year}-{Old} {Children}},
	volume = {24},
	issn = {0891-3668},
	url = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=ovftg&AN=00006454-200501000-00010},
	abstract = {Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135)., Methods: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples., Results: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P {\textless} 0.001 for all comparisons). This significant difference persisted through 6 months., Conclusions: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine., (C) 2005 Lippincott Williams \& Wilkins, Inc.},
	number = {1},
	urldate = {2014-09-13},
	journal = {Journal January 2005},
	author = {Pichichero, Michael and Casey, Janet and Blatter, Mark and Rothstein, Edward and Ryall, Robert and Bybel, Mike and Gilmet, Gregory and Papa, Thomas},
	year = {2005},
	pages = {57--62},
}

Downloads: 0